Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook
Molecules · 2026
DOI: 10.3390/molecules31040684 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Md Ataur Rahman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. Hauptthemen laut MEDLINE: Glioblastoma, Gold, Precision Medicine, Metal Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common malignant primary brain tumor among adults and one of the deadliest human cancers. Its infiltrative growth pattern, high intratumor heterogeneity, and the existence of the blood–brain barrier severely limits current treatment approaches. Precision medicine-guided treatment decision-making based on unique molecular characteristics of patients’ tumors and tumor microenvironments is highly desired. Gold nanoparticles (AuNPs) are promising nanoplatforms that enable precision medicine and personalized treatments for GBM. Their size- and shape-dependent tunable physiochemical properties, ease of surface functionalization, unique optical/electronic properties, and biocompatibility have facilitated the development of AuNP-based multimodal agents with the capability of delivering therapies, molecular imaging, and diagnosis in one platform. Recent research has shown that AuNPs can deliver chemotherapeutics, genes, and immunotherapeutics and aid in imaging, radiosensitization, and photothermal therapy for GBM therapy. Ligand-targeted and stimuli-responsive AuNPs enable site-selective targeting of GBM cells and the tumor microenvironment, allowing for personalized medicine approaches. Here, we review the progress made in biomedical applications of AuNPs for GBM treatment with a focus on precision-based drug/gene delivery, diagnosis/imaging, and therapy enhancement. We also discuss safety, biodistribution, scalability for translation, and regulatory challenges that need to be addressed for AuNP development. Future opportunities for AuNPs in personalizing GBM treatment are also highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
- Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
ORCID-Profile: Md Ataur Rahman, Abdel Halim Harrath
Zitieren
APA
Rahman, M. A., Jalouli, M., Al-Zharani, M., & Harrath, A. H. (2026). Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook. Molecules. https://doi.org/10.3390/molecules31040684
Vancouver
Rahman MA, Jalouli M, Al-Zharani M, Harrath AH. Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook. Molecules. 2026. doi:10.3390/molecules31040684
BibTeX
@article{Rahman2026,
author = {Rahman, Md Ataur and Jalouli, Maroua and Al-Zharani, Mohammed and Harrath, Abdel Halim},
title = {Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31040684}
}
EUVIMED